Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT03330405. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).
Study identification
- NCT ID
- NCT03330405
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 223 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2017 (Actual)
- Primary completion
- Feb 22, 2022 (Actual)
- Completion
- Jan 4, 2023 (Actual)
- Last update posted
- Oct 13, 2023
2017 – 2023
United States locations
- U.S. sites
- 38
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Highlands Oncology | Rogers | Arkansas | 72758 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Highlands Oncology | Springdale | Arkansas | 72762 | — |
| Tower Hematology Oncology Medical Group | Beverly Hills | California | 90211 | — |
| Keck Hospital of USC | Los Angeles | California | 90033 | — |
| LAC+USC Medical Center | Los Angeles | California | 90033 | — |
| USC/Norris Comprehensive Cancer Center/Investigational Drug Services | Los Angeles | California | 90033 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Freidenrich Center for Translational Research (CTRU) | Palo Alto | California | 94304 | — |
| Stanford Cancer Institute | Stanford | California | 94305 | — |
| Stanford Hospital and Clinics | Stanford | California | 94305 | — |
| Stanford Women's Cancer Center | Stanford | California | 94305 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Massachusetts General Hospital (MGH) | Boston | Massachusetts | 02114 | — |
| Massachusetts General Hospital Attn: Lalit Joshi | Boston | Massachusetts | 02114 | — |
| Massachusetts General Hospital Attn: Svetlana Rashkova | Boston | Massachusetts | 02114 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana Farber Cancer Institute, Attn: Vasilika Koci, PharmD | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University Of Minesota Health: Clinics And Surgery Center | Minneapolis | Minnesota | 55455 | — |
| University of Minesota Medical Center, Fairview IDS Pharmacy | Minneapolis | Minnesota | 55455 | — |
| University of Minnesota Medical Center, Fairview | Minneapolis | Minnesota | 55455 | — |
| Roswell Park Cancer Center Institute | Buffalo | New York | 14263 | — |
| NYU Investigational Pharmacy | New York | New York | 10016 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| NYU Langone Radiology | New York | New York | 10016 | — |
| NYU Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| NYU Langone Radiology - Ambulatory Care Center | New York | New York | 10017 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Mount Sinai Hospital- Pharmacy department | New York | New York | 10029 | — |
| Cleveland Clinic Taussig Cancer Center Investigational Pharmacy | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03330405, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03330405 live on ClinicalTrials.gov.